Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Welcome local and national attendees to the first ACRA WEBINAR Sleep Disordered Breathing: A Cardiology Condition – A Sleeping Killer Dr Philip Currie MBBS, FRACP, MBA - Cardiologist and Echocardiographer Local attendees - Emergency exits - Toilet location - Mobile phones (please switch off or turn to silent) - Evaluation forms National attendees - Questions can be typed in left hand side text box - These will be addressed during the presentation - Evaluation to be completed on your screen on completion of event. Next ACRA Webinar THURSDAY 25TH JUNE 2015 - Omega 3 in Cardiovascular Disease Prevention: New Evidence on an old intervention Welcome to country I would like to pay my respects to the Traditional Owners of the land on which we are meeting today. I would also like to pay my respects to elders both past and present. Sleep Important In Wellness and In Disease Sleep Disordered Breathing (SDB) Not Just a Sleep Disorder Heart Condition & Sleeping Killer Maslow’s Hierarchy of Needs Sleep Is Important Sleep Is Part of Wellness Important to Quality of Life Physiological Effects of Sleep Active physiological state - body repair & variety of important functions: Learning and Memory Important for consolidation of new information & memory formation Growth and Development Secretion of growth hormone & prolactin increased during sleep Blood Pressure Chronic short sleep duration increases the risk of hypertension in adults Stress and Metabolism Cortisol & thyrotropin (thyroid stimulating protein) decrease during sleep Appetite Management Ghrelin & leptin hormone levels influence hunger & satiety Obstructive Sleep Apnea Sleep Disordered Breathing (SDB) More Than OSA - A Social Condition Disease Severity & Lack of Recognition Social Condition Snoring Daytime Sleepiness OSA CPAP Retail CPAP Sleep Dr CV Morbidity & Mortality AF HT CAD CHF Stroke Mixed CSA ASV Cardiology What is Sleep-Disordered Breathing? OSA, CSA, and Mixed Sleep Apnea Flow OSA Thorax Abdomen SaO2 100 % 70 Effort Flow CSA Thorax Abdomen SaO2 100 % 70 No Effort 60 sec Physiological Consequences of Sleep Apnea Plunging blood oxygen saturation Negative swings in intra-thoracic pressure Increase in blood pressure Surge sympathetic nerve activity Morgan et al., 1996 Sleep How Do We Measure SDB? Apnea-Hypopnea Index • Based on the total number of complete cessations (apnea) and partial obstructions (hypopnea) of breathing occurring per hour of sleep • These pauses in breathing must last for 10 seconds and are associated with a decrease in oxygenation of the blood >3% • AHI can be used to classify the severity of disease • Mild 5-15 • Moderate 15-30 • Severe >30 Question Why is Sleep Disordered Breathing important in Cardiovascular and Metabolic Diseases? Obesity: A Global Epidemic The Big Elephant (Sumo) in the Room Obesity is Now Socially Accepted Risk Factors for Co-Morbidities Cardiovascular Disease Hyperlipidemia Diabetes Hypertension Obesity OSA Sleep Apnea Prevalence in CV Disease Ubiquitous 80% 70% 35% Logan et al. J. Hypertension 2001 Einhorn et al. Endocrine Prac 2007 50% Javaheri et al. Circulation 1999 50% Somers et al. Circulation 2004 Sjostrom et al. Thorax 2002 30% Schafer et al. Cardiology 1999 30% Sanner et al. Clin Cardiology 2001 Cardiovascular Disease Continuum Adapted from Dzau et al, 2006 Circulation Sleep Apnea – A Cardiovascular Disease Jean-Louis et al., 2010 Expert Rev. Cardiovasc. Ther. SDB and Mortality • 6,294 participants • Average follow up period = 8.2 years • 1.46 X more likely TO DIE with severe SDB • Predictor of mortality – nocturnal hypoxaemia Punjabi et al., 2009 PLoS Medicine Wisconsin Sleep Cohort – 18 year Follow up n = 1396 Young et al., 2008 SLEEP Long Term Fatal and Non-fatal CV Events Worse with More OSA & Better with CPAP • 200-400 subjects per group • Followed for a mean of 10.1 years Marin et al., 2005 Lancet Cumulative Incidence of Hypertension Worse With More Severe OSA n = 1889 Marin et al., 2012 JAMA Atrial Fibrillation and SDB • Multiple mechanistic factors contribute to SDB suggesting SDB induces AF • High incidence of OSA in patients with AF • High incidence of recurrence of AP in first year post DC cardioversion in pts not Rx with CPAP • Risk factor modification reduces recurrent AF post AF ablation (symptoms, AF burden, recurrent ablation) The ARREST-AF Cohort Study Aggressive Risk Factor Reduction Post AF Ablation Pathak et al J Am Coll Cardiol 2014;64:2222 Single-procedure, drug-free, AF-free & Total AF-free Survival Pathak et al J Am Coll Cardiol 2014;64:2222 Obstructive Sleep Apnea and the Risk of Sudden Cardiac Death (SCD) • 10,701 consecutive adults first PSG 1987-2003 • 15 yr follow up SCD - average follow-up of 5.3 yrs, 142 pts had resuscitated or fatal SCD (annual rate 0.27%) • Independent risk factors for SCD - age, hypertension, CAD, cardiomyopathy, heart failure, ventricular ectopy or nonsustained VT, & lowest nocturnal O2 sat • SCD was best predicted by age >60 years (HR: 5.53), AHI >20 (HR: 1.60), mean nocturnal O2sat <93% (HR: 2.93), & lowest nocturnal O2 sat <78% (HR: 2.60; all p < 0.0001) J Am Coll Cardiol 2013;62:610–6) Obstructive Sleep Apnea and the Risk of Sudden Cardiac Death J Am Coll Cardiol 2013;62:610–6) Obstructive Sleep Apnea and the Risk of Sudden Cardiac Death J Am Coll Cardiol 2013;62:610–6) Effect of OSA in Metabolic Syndrome Bonsignore MR et al ERJ 2012 Summary Sleep Disordered Breathing Increases Mortality • CARDIOVASCULAR – SDB is very common and affects prognosis – Cardiovascular diseases are probably the most important consequence of OSA – Assessment of SDB is rapidly becoming a routine part of the management of cardiology patients • DIABETES – OSA and type 2 diabetes frequently coexist – Accumulating evidence that OSA impairs glucose metabolism – Rapidly increasing awareness of OSA in the diabetes community and assessment/management should INCREASE 31 © ResMed 2012 07 Where Else to Go In Heart Failure? Well, this is just going from bad to worse! 32 Lets Invite A Colleague and Sleep On It © ResMed 2012 07 Outline • Heart failure – big problem, need more Rx • Traditional Epiphenomena - LBBB, AF • Sleep Disordered Breathing – more than OSA ? another epiphenomenon • ASV – Adaptive Servo Controlled Ventilation • Schal-HF Registry • SERVE-HF Trial Heart Failure • 300,000 patients in Australia have CHF • Despite recent advances in treatment CHF continues to cause debilitating symptoms • Congestive heart failure leading cause of hospitalisation in >65 years • CHF costly with frequent hospital admissions and deadly. 5 year mortality remains high at 50% Heart Failure – We Need More ! • New interventions that reduce symptoms, increase quality of life, reduce hospital admissions and mortality are needed • It is likely that new interventions will be targeted at specific subgroups of chronic HF patients rather than all CHF pts Heart Failure Management Primary Cardiac Problem Blocking RAS (ACE, ARB, Spironolactone) Blocking SNS (Beta Blocker) LBBB Atrial fibrillation (PVI) SDB (ASV) Add-on Therapy in Heart Failure Each Added Therapy Incrementally Decreases Mortality CHARM AR2B ?? ASV Therapy for SDB ?? LVAD Destination Therapy There remains a 50% 5 year mortality Biventricular Pacing Resynchronising Therapy Current Clinical Trajectory of Patients with HF I II Major costs are incurred for each acute cardiac decompensation inpatient hospital admission III IV Acute events Death Death Optimal Medical Management time LVAD – Left Ventricular Assist Device • Bridge to Transplant • Destination Therapy • Bridge to Recovery • LVAD starting to approach transplant survival in pts not previously transplant candidates SBD International Cardiology Guidelines Committee Sleep Disordered Breathing in Cardiology & CHF “We Await the Evidence of CV Mortality RCT” Why is The Disconnect? The Elephant in The Room • Often OSA overlooked as a reversible CV risk factor • No large-scale, multicentre, randomised control trials of PAP therapy (cholesterol – pre statin) • Ethical challenges (long term no active treatment for symptomatic OSA at risk for car accidents) • Reduced adherence in nonsleepy pts • CSA is indeed Silent But Deadly as the clinical markers of OSA (snoring, witnessed apnoea, daytime sleepiness) are not common • No positive mortality RCT Principal Mechanisms Contributing to SDB in CHF - Important Differences Central Sleep Apnea • • • Pulmonary vagal afferent receptor stimulation Increased central chemo-responsiveness Abnormal cerebrovascular reactivity to pCO2 Obstructive Sleep Apnea • Obesity • Reduced neural output to upper airway muscles • Pharyngeal oedema • Upper airway anatomical abnormalities Bad Cardiovascular Autonomic Effects of OSA Kasai, T. et al. J Am Coll Cardiol 2011;57:119-127 OSA - All Roads Lead to HF Brisco et al., Curr Heart Fail Rep 2010 Pathophysiologic Consequences of CSA in Heart Failure J Am Coll Cardiol. 2015;65(1):72-84 SchlaHF Registry of the SERVE-HF Trial High Prevalence of SDB in CHF • High prevalence of SDB (46%) in stable chronic HF patients • Male gender, age, BMI, severity of both symptoms and LV dysfunction clinical predictors for SDB • Chronic HF patients with SDB often do not show characteristic SDB symptoms • Presence of one or more predictors of SDB (e.g. male, older, obesity, LVEF <25%, NYHA class III/IV or AF) should prompt clinicians to perform device-based screening for SDB Risk factors for SDB in Chronic HF Gender, Age , AF, High BMI Low LVEF - Prevalence of SDB in Stable CHF Populations SchlaHF Registry: PSG data CSA prevalence increases with worsening LV systolic function and increasing NYHA ASV Keywords Adaptive Servo-Ventilation Adaptive: the (pressure) target is adjusted according to the input from the patient, i.e. the target is not a fixed value but instead adapts to patient’s demand Servo-ventilation: closed feedback loop where therapy is designed to achieve a target ventilation (PPM analogy: CPAP =PPM, ASV=PPM, ICD) Adaptive Servoventilation ASV Auto Flow APNEA ASV HYPOPNEA Key Principals of Adaptive Servo-Ventilation ASV • Used to regulate or maintain normal ventilation by correcting the ventilatory pattern of a patient with central sleep apnea (CSA and/or Cheyne-Stokes) • Specifically by: • Stabilizing the upper airway when required, by offering a base level of pressure (EPAP) • Deliver pressure support to stabilise ventilation • Provide patient-machine synchrony How the ASV Determines a Target weighted average mean (3 min) • • On a breath by breath basis minute ventilation is calculated Minute ventilation is monitored using a weighted average mean (3 min window) How the ASV Determines a Target weighted average mean (3 min) • On a breath by breath basis minute ventilation is calculated • Minute ventilation is monitored using a weighted average mean (3 min window) – continually adjusting across the night • Calculates 90% of minute ventilation – target ventilation • If instantaneous minute ventilation < target ventilation ( PS) • If instantaneous minute ventilation > target ventilation ( PS) After ~10-30 mins… Breathing normalised… …and SpO2 stable PAP Therapy in CSA ASV Abolishes CSA Teschler H et. al; AJRCCM 2001 HF – ASV and AHI Meta-Analysis Reduction in AHI Sharma et al., 2012 CHEST HF – ASV and LVEF Improvement in LVEF Sharma et al., 2012 CHEST Pts With Severe Advanced Heart Failure – ASV Decreases CHF Events: A Pooled Meta Analysis Of 629 Pts With CSA J Am Coll Cardiol. 2015;65(10_S) Current Clinical Trajectory of Patients with HF I II Major costs are incurred for each acute cardiac decompensation inpatient hospital admission III IV Acute events Death Death Optimal Medical Management time Current Clinical Trajectory of Patients with HF I Patient with Cheyne Stokes Respiration Prognosis poor II Trajectory without Cheyne Stokes III IV Death Acute events Optimal Medical Management Death Death time Possible Trajectory of HF Patients using ASV Potential for Dramatic Improvement in Economics of Management of Cardiac Failure Patient with Central Sleep Apnea I Trajectory without Central Sleep Apnea II III *ASV? IV Acute events Death Death Routine Clinical Management time *Await final results of SERVE-HF trial & the ADVENT-HF trial late 2016 Treatment Of SDB In Pts Admitted For Decompensated HF Reduces 6 Mth Hospital Visits • 64 patients admitted with CHF underwent PSG within 4 weeks discharge • 60yrs old, BMI 38, 48% male, mean AHI 33 • 29/59 pts (49%) compliant PAP therapy • mean change in hospital visits decreased to 0.7 ± 1.8 visits compliant group vs mean increase of 0.2 ± 1.8 visits for the noncompliant group (paired Wilcoxon test, p=0.03) J Am Coll Cardiol. 2015;65(10_S) SERVE-HF Study Treatment of sleep-disordered breathing with predominant central sleep apnea by adaptive servo ventilation in pts with heart failure SERVE-HF Design • Randomised, multi-centre, outcome study • Parallel group design, comparing control (optimal medical management) with active treatment (optimal medical treatment plus adaptive servoventilation). • Sample size: approx. 1260 patients • 80 active centres • Estimated 20% drop out rate • Estimated minimum follow up of 24 months. SERVE-HF-Study Inclusion Criteria Chronic heart failure LVEF <45% NYHA class III or IV Optimised medical treatment SDB (AHI ≥ 15/h) with > 50% central events and a central AHI ≥ 10/h SERVE-HF-Study Preliminary Results • 1325 pts • Primary end point – All cause mortality or hospitalisation NS difference • Preliminary analysis – significant 2.5% absolute increase in CV mortality in ASV Rx group (10% ASV vs 7.5% per year in control group) • Current ResMed response - avoid ASV in patients who fulfill entry criteria of SERVE-HF trial • Awaiting detailed analysis Summary Sleep is Important in Wellness and In Disease • SDB is very common and increases mortality • CV diseases the most important consequence of OSA • Recognition and management of SDB must become routine in the management of cardiology pts • SDB diagnostics in CV patients (PSG, home based PSG and type 3 screeners) • CSA needs to be recognised due to its prevalence, cheap effective treatment (by cardiology standards) • Greater understanding of ASV – will have greater use • Await cardiology trials (large randomised trials with hard end points (mortality and hospitalisation) • Sleep and SDB major consideration in the holistic management of pts Final Message - Connect the Dots Specifically SDB is a CV Problem Which Kills It must be considered, diagnosed & aggressively managed